Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan A Schmalstig

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|February 22, 2021
Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory InfectionsAlan A Schmalstig, Soha Freidy, Patrick O Hanafin, et al.
Mbio|December 7, 2023
Bacteriophage infection and killing of intracellular <i>Mycobacterium abscessus</i>Alan A Schmalstig, Andrew Wiggins, Debbie Badillo, et al.
Journal of Bacteriology|June 6, 2018
Noncatalytic Antioxidant Role for Helicobacter pylori UreaseAlan A Schmalstig, Stéphane L Benoit, Sandeep K Misra, et al.
Scientific Reports|September 27, 2019
Nickel chelation therapy as an approach to combat multi-drug resistant enteric pathogensStéphane L Benoit, Alan A Schmalstig, John Glushka, et al.
Scientific Reports|November 27, 2019
Author Correction: Nickel chelation therapy as an approach to combat multi-drug resistant enteric pathogensStéphane L Benoit, Alan A Schmalstig, John Glushka, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Inactivating conditions of therapeutic mycobacteriophagesAndrew Wiggins, Umar N Chaudhry, Fabiana Bisaro, et al.
Microbiology Spectrum|February 11, 2026
Inactivating conditions of therapeutic mycobacteriophagesAndrew Wiggins, Umar N Chaudhry, Fabiana Bisaro, et al.
Tuberculosis (Edinburgh, Scotland)|January 25, 2022
Mycobacterium abscessus drug discovery using machine learningAlan A Schmalstig, Kimberley M Zorn, Sebastian Murcia, et al.
ACS Chemical Biology|June 27, 2020
Thiopeptides Induce Proteasome-Independent Activation of Cellular MitophagyKelly E Bird, Christian Xander, Sebastian Murcia, et al.
Nature Communications|August 8, 2022
A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosisManse Kim, Claire E Johnson, Alan A Schmalstig, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|February 22, 2021
Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory InfectionsAlan A Schmalstig, Soha Freidy, Patrick O Hanafin, et al.
Mbio|December 7, 2023
Bacteriophage infection and killing of intracellular <i>Mycobacterium abscessus</i>Alan A Schmalstig, Andrew Wiggins, Debbie Badillo, et al.
Journal of Bacteriology|June 6, 2018
Noncatalytic Antioxidant Role for Helicobacter pylori UreaseAlan A Schmalstig, Stéphane L Benoit, Sandeep K Misra, et al.
Scientific Reports|September 27, 2019
Nickel chelation therapy as an approach to combat multi-drug resistant enteric pathogensStéphane L Benoit, Alan A Schmalstig, John Glushka, et al.
Scientific Reports|November 27, 2019
Author Correction: Nickel chelation therapy as an approach to combat multi-drug resistant enteric pathogensStéphane L Benoit, Alan A Schmalstig, John Glushka, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Inactivating conditions of therapeutic mycobacteriophagesAndrew Wiggins, Umar N Chaudhry, Fabiana Bisaro, et al.
Microbiology Spectrum|February 11, 2026
Inactivating conditions of therapeutic mycobacteriophagesAndrew Wiggins, Umar N Chaudhry, Fabiana Bisaro, et al.
Tuberculosis (Edinburgh, Scotland)|January 25, 2022
Mycobacterium abscessus drug discovery using machine learningAlan A Schmalstig, Kimberley M Zorn, Sebastian Murcia, et al.
ACS Chemical Biology|June 27, 2020
Thiopeptides Induce Proteasome-Independent Activation of Cellular MitophagyKelly E Bird, Christian Xander, Sebastian Murcia, et al.
Nature Communications|August 8, 2022
A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosisManse Kim, Claire E Johnson, Alan A Schmalstig, et al.
Pageof 2